Massachusetts law requires that all recreational marijuana products bear a seal showing they have been tested by a Commission-licensed independent laboratory for contaminants and potency levels.
The American Osteopathic Association supports the reclassification of cannabis as a Schedule II Drug to facilitate advancement in clinical, public health, patient safety and health policy research, according to a resolution approved by the AOA House of Delegates.
Mounting evidence suggests that the inflammatory processes in the brain contribute to the pathologies of Parkinson's, Alzheimer's and HIV-Associated Neurocognitive Disorders.
Achieving ISO/IEC 17025 accreditation is the pinnacle in third-party laboratory accreditation.
A unique cannabis strain that has the capacity to inhibit dendritic-dependent T-cells proliferation has been identified by researchers in Israel.
CBD delivered from Lexaria’s TurboCBDTM capsules was absorbed much more effectively than from the positive control, delivering 317% more CBD to blood at the 30-minute mark of the study.
Whether it is introduced at the cultivator, processor or manufacturer level, ETCH biotrace links a unique molecular tag to the cannabis plant that will survive conversion or extraction.
The grant will fund a series of preclinical studies to determine whether THC consumption during adolescence causes persistent neurological changes.